| |
IQVIA data scientists have created a framework, known as CASTER, to help you identify potential negative drug-drug interactions and account for them during the drug design process. Download the Insight Brief. 
|
|
| By Zoey Becker The CEO is eying some big changes, but he wants to show investors he's prepared to act swiftly, Reuters reports. The publication cited three people "familiar with the matter" in reporting the behind-the-scenes developments at Bayer. |
|
|
|
| Philadelphia, PA |  |
|
|
By Gabrielle Masson GSK’s Senior Vice President and Head of Research John Lepore, M.D., has left the company at the same time the U.K. pharma undergoes a slight shuffling of its R&D operations. |
By Kevin Dunleavy A survey of 100 doctors in the U.S. who prescribe weight loss medications shows that more than 75% consider new obesity drugs from Eli Lilly and Novo Nordisk as “paradigm shifting.” But the physicians also have significant concerns about the cost of the treatments, patient eligibility for coverage and long-term safety risks. |
By Helen Floersh CAR-T cell therapy pioneer Carl June, M.D., and scientists from Vertex Pharmaceuticals are among the life sciences winners of 2024 Breakthrough Prizes, awards established by a group of influential tech titans as a means to recognize major achievements in basic science research. |
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200. 
|
|
By Conor Hale Two technologies were honored with the top prize in biomedical research: one with a history that spans more than three decades and another that made its mark in about a tenth of the time. |
By Fraiser Kansteiner After inspecting Novo’s Clayton, North Carolina, facility between July 6 and July 13, 2023, the FDA officially chided the company for a pair of quality control lapses, according to a Form 483 seen by Fierce Pharma. |
By Kevin Dunleavy For the third time in the last four years, Lonza is seeking a new CEO. The Swiss CDMO on Monday said Pierre-Alain Ruffieux will step down at the end of this month by “mutual agreement.” Chairman Albert Baehny will take over as interim CEO for the second time since 2020. |
By Angus Liu For the JAK inhibitor momelotinib, which GSK obtained in its $1.9 billion acquisition of Sierra Oncology, the three-month extension of the FDA's review turned out to be worth the wait. |
By James Waldron Anyone wanting to end the week on a hopeful note could do worse than to check out the duo of biotech IPOs that made it over the line. RayzeBio has just revealed it overshot expectations by raising $311 million, while Neumora Therapeutics was squarely on target with a $250 million offering. |
By Nick Paul Taylor MAPS Public Benefit Corporation has shown off phase 3 data it hopes will secure a landmark approval for MDMA in the U.S. next year. The second phase 3 success is the result of almost 40 years of work to show that psychedelics can treat post-traumatic stress disorder (PTSD) when used to enhance therapy. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
October 16-17 | Boston, MA Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders. Book your seat today! 
|
|
Whitepaper Read this paper to learn how pharmaceutical and medical device manufacturers can improve their tender and deal management, as well as how to choose a global management platform and the best practices for implementing it. Sponsored by: Cognizant |
Whitepaper Discover five creative and innovative ways to reimagine your legacy biopharma campus and unlock value. Sponsored by: JLL |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how pharma marketers and other players in the industry can ease the way for consumers, ultimately improving health outcomes and boosting adherence in five simple steps. Sponsored by: Healthline Media |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Learn how to close the knowledge gap for cancer patients by increasing awareness of important aspects of their condition, treatment options and support resources. Sponsored by: Phreesia Life Sciences |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
